Table 1 –
Patient characteristics
| RARC (n = 60) | ORC (n = 58) | |
|---|---|---|
| Age (yr), median (IQR) | 66 (60–71) | 65 (58–69) |
| Male sex, n (%) | 51 (85) | 42 (72) |
| ASA score, n (%) | ||
| 2 | 17 (28) | 12 (21) |
| ≥3 | 43 (72) | 46 (79) |
| Clinical stage, n (%) | ||
| ≤T1 | 30 (52) | 24 (42) |
| T2 | 24 (41) | 28 (49) |
| T3 | 4 (6.8) | 5 (8.8) |
| T4 | 1 (1.7) | 0 (0) |
| Neoadjuvant chemotherapy, n (%) | 19 (32) | 26 (45) |
| Pathologic stage, n (%) | ||
| T0 | 13 (22) | 7 (12) |
| Tis | 14 (23) | 11 (19) |
| Ta | 1 (1.7) | 3 (5.2) |
| T1 | 7 (12) | 11 (19) |
| T2 | 8 (13) | 7 (12) |
| T3 | 12 (20) | 15(26) |
| T4 | 5 (8.3) | 4 (6.9) |
| Histology, n (%) | ||
| Urothelial cell carcinoma | 57 (95) | 55 (95) |
| Small cell carcinoma | 1 (1.7) | 1 (1.7) |
| Small cell plus TCC | 1 (1.7) | 0 (0) |
| Squamous cell carcinoma | 1 (1.7) | 1 (1.7) |
| Adenocarcinoma | 0 (0) | 1 (1.7) |
| Lymph node yield, mean (SD) | ||
| Extended dissection | 31.9 (12) | 30 (12) |
| Standard dissection | 19.5 (10) | 18.9 (10) |
| Lymph node-positive patients, n (%) | 10 (18) | 9 (15) |
| Positive surgical margin, n (%) | 2 (3.6) | 3 (4.8) |
ASA = American Society of Anesthesiologists; IQR = interquartile range; ORC = open radical cystectomy; RARC = robot-assisted radical cystectomy; SD = standard deviation; TCC = transitional cell carcinoma.